The synergistic effect of axitinib with immunotherapy has been demonstrated to enhance T-cell infiltration in tumours, thereby partially counteracting immunosuppression in PD-L1-negative patients (Atkins MB, et al., 2018). This evidence concerns the gene CD274 and neoplasm.